222 related articles for article (PubMed ID: 33592498)
1. CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens.
Forlani G; Michaux J; Pak H; Huber F; Marie Joseph EL; Ramia E; Stevenson BJ; Linnebacher M; Accolla RS; Bassani-Sternberg M
Mol Cell Proteomics; 2021; 20():100032. PubMed ID: 33592498
[TBL] [Abstract][Full Text] [Related]
2. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.
Soos JM; Krieger JI; Stüve O; King CL; Patarroyo JC; Aldape K; Wosik K; Slavin AJ; Nelson PA; Antel JP; Zamvil SS
Glia; 2001 Dec; 36(3):391-405. PubMed ID: 11746775
[TBL] [Abstract][Full Text] [Related]
3. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
4. [Major histocompatibility complex class II transactivator (CIITA) hammer- head ribozyme transfer inhibits major histocompatibility complex class II (MHC-II) expression in Jukart cells].
Guo R; Zou P; Song YP; Ma J; Lu HZ; Cao YL; Tong YJ
Zhonghua Er Ke Za Zhi; 2003 Dec; 41(12):925-8. PubMed ID: 14723817
[TBL] [Abstract][Full Text] [Related]
5. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
6. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.
Sartoris S; Valle MT; Barbaro AL; Tosi G; Cestari T; D'Agostino A; Megiovanni AM; Manca F; Accolla RS
J Immunol; 1998 Jul; 161(2):814-20. PubMed ID: 9670958
[TBL] [Abstract][Full Text] [Related]
7. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
[TBL] [Abstract][Full Text] [Related]
8. Toxoplasma gondii inhibits MHC class II expression in neural antigen-presenting cells by down-regulating the class II transactivator CIITA.
Lüder CG; Lang C; Giraldo-Velasquez M; Algner M; Gerdes J; Gross U
J Neuroimmunol; 2003 Jan; 134(1-2):12-24. PubMed ID: 12507768
[TBL] [Abstract][Full Text] [Related]
9. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.
Accolla RS; Ramia E; Tedeschi A; Forlani G
Front Immunol; 2019; 10():1806. PubMed ID: 31417570
[TBL] [Abstract][Full Text] [Related]
10. Cancer-specific T helper shared and neo-epitopes uncovered by expression of the MHC class II master regulator CIITA.
Hos BJ; Tondini E; Camps MGM; Rademaker W; van den Bulk J; Ruano D; Janssen GMC; de Ru AH; van den Elsen PJ; de Miranda NFCC; van Veelen PA; Ossendorp F
Cell Rep; 2022 Oct; 41(2):111485. PubMed ID: 36223747
[TBL] [Abstract][Full Text] [Related]
11. Functional disruption of human leukocyte antigen II in human embryonic stem cell.
Chen H; Li Y; Lin X; Cui D; Cui C; Li H; Xiao L
Biol Res; 2015 Oct; 48():59. PubMed ID: 26506955
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of HLA-II related to LAG-3
Guo W; Peng D; Liao Y; Lou L; Guo M; Li C; Yu W; Tian X; Wang G; Lv P; Zuo J; Shen H; Li Y
Cancer Sci; 2024 May; 115(5):1388-1404. PubMed ID: 38480275
[TBL] [Abstract][Full Text] [Related]
13. Selective modulation of MHC class II chaperons by a novel IFN-γ-inducible class II transactivator variant in lung adenocarcinoma A549 cells.
Chiu BL; Li CH; Chang CC
Biochem Biophys Res Commun; 2013 Oct; 440(1):190-5. PubMed ID: 24055710
[TBL] [Abstract][Full Text] [Related]
14. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
15. γ-Interferon-regulated chaperone governs human lymphocyte antigen class II expression.
Kämper N; Franken S; Temme S; Koch S; Bieber T; Koch N
FASEB J; 2012 Jan; 26(1):104-16. PubMed ID: 21940994
[TBL] [Abstract][Full Text] [Related]
16. MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity.
Benasciutti E; Mariani E; Oliva L; Scolari M; Perilli E; Barras E; Milan E; Orfanelli U; Fazzalari NL; Campana L; Capobianco A; Otten L; Particelli F; Acha-Orbea H; Baruffaldi F; Faccio R; Sitia R; Reith W; Cenci S
J Bone Miner Res; 2014 Feb; 29(2):290-303. PubMed ID: 24038328
[TBL] [Abstract][Full Text] [Related]
17. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
Meissner M; Whiteside TL; Kaufmann R; Seliger B
Arch Dermatol Res; 2009 Feb; 301(2):189-93. PubMed ID: 19104823
[TBL] [Abstract][Full Text] [Related]
18. Class II transactivator (CIITA) isoform expression and activity in melanoma.
Baton F; Deruyffelaere C; Chapin M; Prod'homme T; Charron D; Al-Daccak R; Alcaide-Loridan C
Melanoma Res; 2004 Dec; 14(6):453-61. PubMed ID: 15577315
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells.
Liu A; Takahashi M; Toba K; Zheng Z; Hashimoto S; Nikkuni K; Furukawa T; Koike T; Aizawa Y
Hematol Oncol; 1999 Dec; 17(4):149-60. PubMed ID: 10725870
[TBL] [Abstract][Full Text] [Related]
20. RB and a novel E2F-1 binding protein in MHC class II deficient B-cell lines and normal IFN-gamma induction of the class IL transactivator CIITA in class II non-inducible RB-defective tumor lines.
Tschickardt ME; Lu Y; Jacim M; Ussery GD; Steimle V; Mach B; Blanck G
Int J Cancer; 1995 Aug; 62(4):461-5. PubMed ID: 7635572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
